Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
Chronic disease patients seek online support and information, and show little love for branded websites.
News on Modern Healthcare, Journal of Lawand Biosciences and Neuro-Oncology
Drugmakers looking for wiggle room should keep such hopes far from any drugs with a boxed warning.